Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure - Full Text View

Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure (CARNEBI)

This study has been completed.

First Received on August 16, 2007. Last Updated on September 15, 2010 History of Changes

Sponsor:	Centro Cardiologico Monzino
Information provided by:	Centro Cardiologico Monzino
ClinicalTrials.gov Identifier:	NCT00517725

Purpose

The investigators test the hypothesis that different beta-blockers had a different influence on chemoreceptor response and lung diffusion capacity.

Both could influence exercise capacity in normoxic as well as hypoxic conditions.

Condition	Intervention	Phase
Chronic Heart Failure	Drug: carvedilol Drug: bisoprolol Drug: Nebivolol	Phase 4

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment
Official Title:	Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function

Resource links provided by NLM:

MedlinePlus related topics: Exercise and Physical Fitness Heart Failure

Drug Information available for: Carvedilol Bisoprolol fumarate Nebivolol Nebivolol Hydrochloride

U.S. FDA Resources

Further study details as provided by Centro Cardiologico Monzino:

Primary Outcome Measures:

exercise capacity [ Time Frame: two months ]

Secondary Outcome Measures:

lung diffusion [ Time Frame: two months ]

Enrollment:	60
Study Start Date:	July 2007
Study Completion Date:	May 2010

Arms	Assigned Interventions
Active Comparator: Carvedilol	Drug: carvedilol
Active Comparator: Bisoprolol	Drug: bisoprolol
Active Comparator: Nebivolol	Drug: Nebivolol

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Chronic heart failure patients in stable clinical condition

Exclusion Criteria:

No comorbidity
NYHA class IV

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00517725

Locations

Italy
Centro Cardiologico Monzino, University of Milan
Milan, Italy, 20138

Sponsors and Collaborators

Centro Cardiologico Monzino

Investigators

Principal Investigator:	Piergiuseppe Agostoni, MD, PhD	Centro Cardiologico Monzino
Study Chair:	Giancarlo Marenzi, MD	Centro Cardiologico Monzino

More Information

Publications:

Agostoni P, Bussotti M, Cattadori G, Margutti E, Contini M, Muratori M, Marenzi G, Fiorentini C. Gas diffusion and alveolar-capillary unit in chronic heart failure. Eur Heart J. 2006 Nov;27(21):2538-43. Epub 2006 Oct 6.

Responsible Party:	Piergiuseppe Agostoni, Centro Cardiologico Monzino - Univeristy of Milan
ClinicalTrials.gov Identifier:	NCT00517725 History of Changes
Other Study ID Numbers:	R76-CCM S78/407
Study First Received:	August 16, 2007
Last Updated:	September 15, 2010
Health Authority:	Italy: Ministry of Health

Keywords provided by Centro Cardiologico Monzino:

exercise
lung diffusion
hypoxia

chemoreceptor
beta-blockers
heart failure

Additional relevant MeSH terms:

Heart Failure
Heart Diseases
Cardiovascular Diseases
Carvedilol
Nebivolol
Bisoprolol
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Sympatholytics
Autonomic Agents

Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists

ClinicalTrials.gov processed this record on May 22, 2012